NCT01760993
- Objective
- Evaluate SPD489 in schizophrenia
- Design
- Not yet disclosed
- Participants
- Not yet disclosed
- Primary endpoint
- Not yet disclosed
- Results
- Results not yet reported; trial associated with terminated Phase 3 program
pharma · Diabetes Mellitus · Hemophilia A
Takeda
Takeda is a pharma organization headquartered in Cambridge, USA. Primary therapeutic focus areas include Diabetes Mellitus, Hemophilia A, Crohn's Disease, Hypertension, Type 2 Diabetes Mellitus. NovaPharmaNews links 1179
Cambridge, USA HQ
1993 Founded
1,617 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Cambridge, USA
- Founded
- 1993
- Employees
- 1,617
- Programs
- 1179
- Drugs
- 359
- Patents
- 1436
SPD489
Phase 3 · small molecule · Schizophrenia
SPD489 is a small-molecule therapeutic candidate developed by Takeda for the treatment of schizophrenia. The program reached Phase 3 clinical development but was terminated, with the latest milestone recorded on 22 June 2021. The mechanism of action and specific molecular target have not been disclosed. As a Takeda-spo
Internal code SPD489-336
At a glance
- Sponsor
- Takeda
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Schizophrenia
- Status
- terminated
- Trials
- 1
Executive summary
SPD489 is a small-molecule therapeutic candidate developed by Takeda for the treatment of schizophrenia. The program reached Phase 3 clinical development but was terminated, with the latest milestone recorded on 22 June 2021. The mechanism of action and specific molecular target have not been disclosed. As a Takeda-sponsored program with no disclosed partner arrangement, SPD489 represents an internal development effort in the competitive antipsychotic space. The termination of the Phase 3 program indicates that Takeda made a strategic decision to discontinue development, though the specific rationale has not been publicly disclosed. The program was supported by clinical trial NCT01760993, which evaluated the candidate in the schizophrenia indication. Given the crowded competitive landscape of approved antipsychotics and the program's termination status, SPD489 is no longer advancing toward regulatory approval or commercialization.
Why this program matters
Schizophrenia represents a significant unmet medical need affecting millions of patients globally, with existing approved therapies including clozapine, iloperidone, aripiprazole, paliperidone ER, and others. The antipsychotic market remains highly competitive, with multiple mechanism classes and formulation strategies (oral, long-acting injectables) already established. New entrants must demonstrate clear clinical advantages over existing standard-of-care treatments to justify development investment and secure market adoption. SPD489's termination in Phase 3 suggests that Takeda's internal assessment determined the program did not meet predefined efficacy, safety, or commercial viability thresholds relative to the competitive landscape. The decision to discontinue reflects the high bar for success in psychiatric drug development, where regulatory approval alone is insufficient without differentiated clinical benefit or improved tolerability profiles. For patients, the termination removes one potential treatment option but does not materially impact the current availability of antipsychotic therapies. From a commercial perspective, Takeda's portfolio includes approved psychiatric agents such as vortioxetine and ramelteon, suggesting the company continues to invest in CNS therapeutics despite the SPD489 setback. The program's failure underscores the challenges of bringing novel antipsychotics to market in an era of established, cost-effective generic competition and well-characterized safety profiles of existing agents.
Drug intelligence
Drug Class: Antipsychotic (small-molecule)
Modality: Small molecule
Mechanism of Action: Not yet disclosed
Molecular Target: Not yet disclosed
Route of Administration: Not yet disclosed
Related Therapies: Other approved antipsychotics in the schizophrenia market include clozapine, iloperidone, aripiprazole, paliperidone ER, and perindopril-based formulations. Takeda's own approved CNS portfolio includes vortioxetine (depression/anxiety) and ramelteon (sleep disorders).
Patent Status: Not yet disclosed
First Approval: Program terminated; not approved
schizophrenia
Also known as: schizophrenia 12, schizophrenia (disease), SCZD
Overview
A major psychotic disorder characterized by abnormalities in the perception or expression of reality. It affects the cognitive and psychomotor functions. Common clinical signs and symptoms include delusions, hallucinations, disorganized thinking, and retreat from reality.
Treatment landscape
ClinicalTrials.gov lists 2,921 registered studies for Schizophrenia (AACT aggregate).
Phase breakdown: NA (1,441), PHASE4 (414), PHASE3 (377), PHASE2 (297), PHASE1 (276), PHASE1/PHASE2 (52), PHASE2/PHASE3 (42), EARLY_PHASE1 (22)
Common investigational therapies:
- Placebo
- Aripiprazole
- Risperidone
- Olanzapine
- placebo
- risperidone
- Paliperidone ER
- Ziprasidone
- olanzapine
- Quetiapine
Disease data sourced from MONDO Disease Ontology (MONDO:0005090), Orphanet — schizophrenia, NCT00000371, NCT00000372, NCT00000374, NCT00000387, NCT00001192, AACT (ClinicalTrials.gov aggregate), ClinicalTrials.gov, Open Targets Platform (CC BY 4.0).
Clinical development timeline
- Phase 3TBD
Phase 3 ongoing
SPD489-336 Phase 3 trial (NCT01760993) was active in schizophrenia indication.
- Phase 32021-06-22
Program terminated
Latest milestone recorded; program status changed to terminated as of this date.
Competitive landscape
SPD489 entered a mature antipsychotic market with multiple approved small-molecule competitors. Established therapies include clozapine (Bright Minds Biosciences), iloperidone (Vanda Pharmaceuticals), aripiprazole (Otsuka Beijing Research Institute), and paliperidone ER (Hospital Authority, Hong Kong). Long-acting formulations such as PERSERIS (Indivior) represent an alternative delivery strategy. Takeda itself markets vortioxetine and ramelteon in the CNS space, indicating ongoing investment in psychiatric and neurological indications. Newer entrants such as INTENSIFY SZ (Disc Medicine) and adjunctive therapies like valbenazine (Neurocrine Biosciences) and dexmedetomidine (BioXcel Therapeutics) address specific symptom clusters or treatment-resistant populations. The competitive environment is characterized by generic competition, established safety and efficacy data for first- and second-generation antipsychotics, and increasing focus on long-acting injectables and formulations targeting treatment-resistant schizophrenia. SPD489's termination in Phase 3 suggests the program could not differentiate sufficiently from this competitive field to justify continued development investment or achieve regulatory approval with a favorable risk-benefit profile.
| Therapy | Company | Mechanism | Status |
|---|---|---|---|
| Clozapine | BRIGHT MINDS BIOSCIENCES INC. | small_molecule | approved |
| Iloperidone | Vanda Pharmaceuticals Netherlands B.V. | small_molecule | approved |
| Ramelteon | Takeda | small_molecule | approved |
| PERSERIS | Indivior Pty Ltd | small_molecule | approved |
| INTENSIFY SZ | Disc Medicine | small_molecule | approved |
| Varenicline | BRIGHT MINDS BIOSCIENCES INC. | small_molecule | approved |
| Aripiprazole | Otsuka Beijing Research Institute | small_molecule | approved |
| Paliperidone ER | Hospital Authority, Hong Kong | small_molecule | approved |
| Vortioxetine | Takeda | small_molecule | approved |
| Valbenazine | NEUROCRINE BIOSCIENCES INC | small_molecule | approved |
| Minocycline | BRIGHT MINDS BIOSCIENCES INC. | small_molecule | approved |
| Dexmedetomidine | BioXcel Therapeutics | small_molecule | approved |
| ZIPRASIDONE HYDROCHLORIDE | — | Dopamine D2 receptor antagonist | Approved |
| TRIFLUOPERAZINE HYDROCHLORIDE | — | D2-like dopamine receptor antagonist | Approved |
| THIOTHIXENE | — | Dopamine D2 receptor antagonist | Approved |
| SAMIDORPHAN L-MALATE | — | Delta opioid receptor partial agonist | Approved |
| RISPERIDONE | — | Serotonin 2a (5-HT2a) receptor antagonist | Approved |
| QUETIAPINE FUMARATE | — | Serotonin 2c (5-HT2c) receptor antagonist | Approved |
| PROCHLORPERAZINE | — | Dopamine D2 receptor antagonist | Approved |
| PERPHENAZINE | — | Dopamine D2 receptor antagonist | Approved |
Additional associated therapies sourced from Open Targets Platform (CC0), linked to NovaPharmaNews drug profiles where matched.
Regulatory intelligence
FDA Status: Not yet disclosed; program terminated in Phase 3, no approval filed or granted.
EMA Status: Not yet disclosed.
PMDA (Japan) Status: Not yet disclosed.
NMPA (China) Status: Not yet disclosed.
SPD489 did not advance to regulatory submission. The termination on 22 June 2021 ended the development program prior to any formal regulatory filing. No approval pathway, breakthrough designation, or regulatory guidance has been disclosed.
Clinical evidence summary
Key questions answered
What is SPD489?
SPD489 is a small-molecule antipsychotic candidate developed by Takeda for schizophrenia treatment. The program was terminated in Phase 3 clinical development in June 2021.
Is SPD489 approved by the FDA?
No. SPD489 was terminated in Phase 3 and never submitted for FDA approval or any other regulatory authorization.
Who manufactures or developed SPD489?
Takeda Pharmaceutical Company developed SPD489 internally; no partner or co-developer has been disclosed.
What is the mechanism of action of SPD489?
The mechanism of action has not been disclosed by Takeda.
What is the molecular target of SPD489?
The specific molecular target has not been disclosed.
What clinical trial supported SPD489?
NCT01760993 was the primary disclosed trial evaluating SPD489 in schizophrenia; detailed results have not been reported.
When was SPD489 terminated?
SPD489 was terminated on 22 June 2021, while in Phase 3 development.
Why was SPD489 terminated?
The specific rationale for termination has not been disclosed by Takeda.
What is the indication for SPD489?
SPD489 was being developed for the treatment of schizophrenia.
What phase was SPD489 in when terminated?
SPD489 was in Phase 3 clinical development when the program was terminated.
Does Takeda have other antipsychotic programs?
Takeda markets vortioxetine for depression and anxiety, and ramelteon for sleep disorders, but SPD489 was the company's disclosed antipsychotic candidate in development.
What are the main competitors to SPD489 in schizophrenia?
Approved competitors include clozapine, iloperidone, aripiprazole, paliperidone ER, and long-acting formulations such as PERSERIS.
Is there a partner for SPD489?
No partner or licensing arrangement has been disclosed; SPD489 was developed internally by Takeda.
What is the route of administration for SPD489?
The route of administration has not been disclosed.
Will SPD489 ever be developed again?
No indication has been given that Takeda plans to restart SPD489 development; the program remains terminated as of the latest available information.
Are there any published results from SPD489 trials?
No published results from NCT01760993 or other SPD489 trials have been disclosed in the available information.
Entity relationship graph
SPD489 → Drug → Target → Indication → Company → Trials → Competitors
Companies
Indication
Trials
Analyst insights
Strategic Implications: Takeda's termination of SPD489 in Phase 3 reflects a disciplined approach to R&D portfolio management. The decision to discontinue suggests internal data did not support a competitive advantage over existing antipsychotics or did not meet predefined commercial thresholds. This is consistent with industry trends toward higher bar for approval in psychiatric indications, where regulatory approval without clinical differentiation faces reimbursement and adoption barriers.
Competitive Implications: The termination removes one potential entrant from an already crowded antipsychotic market. Takeda's continued investment in other CNS programs (vortioxetine, ramelteon) indicates the company remains active in psychiatry and neurology, but SPD489 did not meet the company's advancement criteria. Competitors with approved agents or programs in late-stage development face no new threat from SPD489.
Future Catalysts: None anticipated; program is terminated. No further clinical data, regulatory submissions, or approvals are expected from SPD489.
Expected Milestones: No future milestones are expected. The program concluded with termination in June 2021.
Quick answers
Concise, citable answers optimized for AI answer engines.
- What is SPD489?
- Small-molecule antipsychotic candidate by Takeda for schizophrenia; terminated Phase 3 in June 2021.
- Sponsor of SPD489?
- Takeda Pharmaceutical Company.
- Indication for SPD489?
- Schizophrenia.
- Current status of SPD489?
- Terminated; no longer in development.
- What phase was SPD489 in?
- Phase 3 clinical development.
- Modality of SPD489?
- Small molecule.
- Mechanism of action of SPD489?
- Not disclosed.
- Molecular target of SPD489?
- Not disclosed.
- Is SPD489 approved?
- No; program terminated before regulatory submission.
- Route of administration for SPD489?
- Not disclosed.
- Partner for SPD489?
- None disclosed; Takeda internal program.
- When was SPD489 terminated?
- 22 June 2021.
- Clinical trial for SPD489?
- NCT01760993 in schizophrenia; results not reported.
- Why was SPD489 terminated?
- Rationale not disclosed by Takeda.
- Key competitors to SPD489?
- Clozapine, iloperidone, aripiprazole, paliperidone ER, PERSERIS.
- Will SPD489 be restarted?
- No indication; program remains terminated.
- Patent status of SPD489?
- Not disclosed.
- First disclosure date of SPD489?
- Not yet disclosed.
- Peak sales projection for SPD489?
- Not disclosed; program terminated.
- Lead investigator for SPD489?
- Not disclosed.
- Internal code for SPD489?
- SPD489-336.
- Is SPD489 a Takeda drug?
- Yes; developed internally by Takeda; now terminated.
Evidence & sources
- ClinicalTrials.gov NCT01760993 (clinicaltrials)
- Source: phase (source_attribution)
- MONDO Disease Ontology (MONDO:0005090) (mondo)
- Orphanet — schizophrenia (orphanet)
- NCT00000371 (clinicaltrials_gov)
- NCT00000372 (clinicaltrials_gov)
- NCT00000374 (clinicaltrials_gov)
- NCT00000387 (clinicaltrials_gov)
- NCT00001192 (clinicaltrials_gov)
- AACT (ClinicalTrials.gov aggregate) (aact)
- ClinicalTrials.gov (clinicaltrials_gov)
- Open Targets Platform (opentargets)
Intelligence compiled from public regulatory and clinical sources (FDA, EMA, ClinicalTrials.gov and company disclosures). Figures may be editorial or analyst estimates; verify against primary sources before relying on them.